Two lab leads layer mass accuracy, sequencing and checks for D- or L-amino acids, which they say regulators increasingly expect for peptide drugs.
Recap by typeshit. Full story at LCGC International.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
The advisory committee voted to return six peptides barred in 2023, over FDA staff objections. The author argues the GLP-1 shortage proved compounders can deliver.
A short lipidated peptide pulled Nav1.8 pain channels off nerve cell surfaces in a Cell Reports Medicine study. The company says several candidates are now in evaluation.
Loading…